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During the past ten years the field of human disease genetics has made major leaps, including the
completion of the Human Genome Project, the HapMap Project, the development of the genome-wide
association (GWA) studies to identify common disease-predisposing variants and the introduction of
large-scale whole-genome and whole-exome sequencing studies. The introduction of new technologies
has enabled researchers to utilize novel study designs to tackle previously unexplored research questions
in human genomics. These new types of studies typically need large sample sizes to overcome the
multiple testing challenges caused by the huge number of interrogated genetic variants. As a
consequence, large consortia-studies are at present the default in disease genetics research. The
systematic planning of the GWA-studies was a key element in the success of the approach. Similar
planning and rigor in statistical inferences will probably be beneficial also to future sequencing studies.
Already today, the next-generation exome sequencing has led to the identification of several genes
underlying Mendelian diseases. In spite of the clear benefits, the method has proven to be more
challenging than anticipated. In the case of complex diseases, next-generation sequencing aims to
identify disease-associated low-frequency alleles. However, their robust detection will require very large
study samples, even larger than in the case of the GWA-studies. This has stimulated study designs that
capitalize on enriching sets of low-frequency alleles, for example, studies focusing on population isolates
such as Finland or Iceland. One example is the collaborative SISu Project (Sequencing Initiative Suomi)
that aims to provide near complete genome variation information from Finnish study samples and pave
the way for large, nationwide genome health initiative studies.During the ten years that the ESF Functional Genomics program
has existed, our thinking and tools to improve the understanding
of the genetic background of diseases has transformed substan-
tially. In 2002, when the program started, the first draft of the
human genome had just been launched. Trying to understand the
genetic background of common diseases, our thinking at that time
was heavily influenced by our previous success to identify gene
mutations causing Mendelian (monogenic) diseases. The thought
was that similar family-based positional cloning strategies used toCorresponding author: Palotie, A. (aarno.palotie@helsinki.fi), (aarno@sanger.ac.uk)
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case of complex traits. However, the underlying genetic architec-
ture of complex diseases turned out to be fundamentally different
from those in classical Mendelian diseases thereby needing differ-
ent study designs and tools. The vision for complex disease genet-
ics was highlighted already in 1996 when Risch and Merikangas [1]
pointed out that association studies are far more powerful than
linkage studies in detecting multiple variants with small effect
sizes. However, at that time, our tools were not yet sufficiently
developed to implement these visions in practice. During the past
ten years, that is, during the lifetime of the ESF program, the tools1.013 www.elsevier.com/locate/nbt 291
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tant contributions being the drop in the cost of genotyping and
sequencing.
As family-based linkage studies had modest success in identify-
ing variants associated with the pathogenesis of common diseases,
the contrary is true for the genome-wide association (GWA) stu-
dies. The work of the International HapMap consortium created a
map of sequence variants common in the population (http://
hapmap.ncbi.nlm.nih.gov/) that the industry used to develop
standardized, cost-effective genotyping platforms. This enabled
the genotyping of hundreds of thousands of variants in each
individual study subject. Already the first GWA-studies clearly
showed that the GWA-strategy is a successful method to detect
associations between common polymorphisms and complex dis-
eases and traits. As of July 2012, the GWA-study catalogue (http://
www.genome.gov/gwastudies/) lists 1324 publications reporting
robust associations between 6735 SNP markers and hundreds of
diseases and traits [2].
By contrast, it also quickly became clear that most of the
associated variants have very modest effect sizes (Odds ratios
between 1.1 and 1.4). This inevitably means that GWA-studies
need large sample sizes; samples from the low thousands up to
hundreds of thousands are needed to pinpoint true associations
among hundreds of thousands of markers with high statistical
power. The need for large sample sizes beyond what individual
study sites are able to collect quickly changed the mode of how
genetic research is carried out. This new mode follows the global,
collaborative pattern initially set by the Human Genome Project.
No clinical center can work by them selves anymore. The groups
had, and still have, to combine their resources to achieve mean-
ingful statistical power. This was a major paradigm change in how
academic research in this field is carried out. The necessity of large
collaborative studies also had its impact on the funding structure.
Large studies are expensive, beyond the reach of traditional aca-
demic funding modules, for example, the RO1 mechanism in US.
Also in Europe, national and EU frameworks had a hard time (and
still have) to respond to this quick change.
Lessons from GWA studies to guide us to design
sequencing studies
One important lesson from the success of the GWA-era was that it
is crucial to carefully and systematically build large collaborative
networks. For example, the early collaboration between the aca-
demic HapMap scientists and the genotype reagent industry was a
key-element that drove the development of standardized genotyp-
ing platforms that the research field needed. These commercial
genotyping chips were subsequently used in laboratories around
the world, which enabled straightforward combination of data for
subsequent meta-analyses.
Another lesson was that a solid statistical framework for study
design and data analysis should be developed early on. In the GWA-
studies, this consisted of strategies to control for genotype measure-
ment errors, standardized approaches to control for confounding
due to differential allele frequencies across populations and the
multiple testing burden. It also included strategies for replication
and validation of associations. As a result, the GWA-studies have
implicated an avalanche of novel candidate genes and regions for
functional studies. The well-defined statistical framework saved the292 www.elsevier.com/locate/nbtfield from a lot of unnecessary confusion. Now, when we have
moved towards sequence-based low-frequency variant association
studies, the benefits for setting rigorous statistical framework early
on should be kept in mind.
From the GWA locus to function
GWA-studies have been criticized for that they only provide
information on genetic loci but no functional insight. Although
we think that the critique in part is unjustified, it nonetheless
highlights an important next step of the research. However, at
present the field of functional biology is lacking efficient tools to
shed more light on the function of the associated variants. One
challenge is that the effect size of each individual variant is small
and thus it is not trivial to develop readouts for cell- or model
organism-based assays that reliably monitor small changes, e.g. in
gene expression or phenotypes. Knock out assays may be a prac-
tical approach to elucidate gene function. Yet it is not an optimal
model to decipher the in vivo consequence of genome variation
with modest functional consequences. Secondly, the associated
variants do not work in isolation. In some cases there is evidence
that some cumulative effects of variants are additive [3], but there
is also evidence that some variants can compensate for the effect of
others [4]. Thirdly, most of the associated loci are located outside
the coding regions of genes. Our understanding of the function
and relevance of these intergenic, probably regulatory, regions is
limited. This limited knowledge certainly limits the design of
follow-up experiments. Large collaborative initiatives such as
the ENCODE (Encyclopedia of DNA Elements) project aim to
improve our understanding of the function of the genome. It
provides new genome-wide tools to link disease-associated gene
variants to gene function. One example is the open chromatin
assays, including mapping of DNAase I hypersensitive sites in a
large panel of cell lines (http://www.genome.gov/10005107).
Towards a more complete understanding of the human
genome variation
The success of the GWA-studies stimulated the field to proceed to
provide an even more comprehensive understanding of the asso-
ciation of disease risk with genome variations. The introduction
of new sequencing technologies and the dramatic drop of sequen-
cing costs made it possible to explore the human variation in
more detail. The first international effort was the 1000 genome
project that aims to establish an extensive catalogue of human
variations from 25 populations (www.1000genomes.org). The
1000 genomes project consists of anonymous participants with-
out any phenotype information. Thus its main aim is to provide
an international open access resource that serves as a basis for
subsequent phenotype related studies. The 1000 genome project
has been followed by large disease-specific sequencing studies, for
example, the UK10K (www.UK10K.org) and GoT2D (Genetics of
Type 2 Diabetes).
Medical genome- and exome sequencing
The excitement of low cost sequencing has stimulated a boom of
whole-genome and whole-exome sequencing studies. There are
several successful examples of the identification of Mendelian
gene mutations using new sequencing techniques (for references
see [5]). At the same time, the challenges of this approach have also
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FIGURE 1
Statistical power to detect association between various low frequency
variants, effect sizes, and disease for sample size of 2000 cases and 2000
controls. P < 5  108 is assumed for genome-wide significant association.
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identification of functional disease causing mutations from more
than 20,000 variants in each exome sample is not trivial. The
interpretation of homozygote recessive mutations is typically the
most straightforward. Even that is not always easy. However, the
situation becomes much more complicated when we search for
dominant acting variants, even if they were highly penetrant
mutations. Each of us carries on an average 100 loss-of-function
variants in our genome, 20 of which are in homozygous form [6].
We have very little understanding which of them, if any, may
contribute to a phenotype. Thus detecting a loss-of-function
variant in one sample has limited (if any) power to prove causality.
The situation becomes even more complicated if the high-pene-
trant variant is a missense variant; each of us carries thousands of
missense variants [5].
Some of the early attempts to identify Mendelian mutations
using exome- or whole-genome sequencing were driven by high
enthusiasm and sometimes not fully appreciating the statistical
challenges of the study. Back in 1990s and early 2000, at the peak
of positional cloning studies of Mendelian traits, rigorous stan-
dards were used before a mutation could be declared as disease-
causing. Typically, the chromosomal location was first pinpointed
by linkage, applying generally agreed significance thresholds. If a
variant in the linked region was not seen in the background
population, the same or different variants in the same gene had
to be associated with the same phenotype in replication studies.
Thirdly, at least some functional data had to be presented to
convince the field, and the reviewers, that this variation/mutation
was associated with the phenotype. It is hard to think of a reason
why a more relaxed framework should be applied in exome
sequence-based variant identification.
Identification of low frequency variants contributing to
common diseases
The identification of lower frequency variations (range 0.5–5%
frequency in the general population) contributing to common
diseases is expected to further expand our knowledge of the
genetic background of these traits. One could expect that low-
frequency variants will shed light especially on our understand-
ing of disease mechanisms involved in the tails of a disease
distribution. However, if we assume that the penetrance (risk
ratio) of very low frequency alleles is modest and possibly only
slightly higher than in the case of common variants (e.g. RR 1.2–
2.0), the study size needed to achieve sufficient power is enor-
mous. Given that it is complicated to reach significance in Men-
delian traits, the challenge is even harder in case of common
diseases [5]. Yet, discoveries such as the identification of low-
frequency variants associating with sick sinus syndrome, gout and
protection of Alzheimer’s disease in the Icelandic population
prove that with appropriate study designs and rigorous statistical
methods in low/rare-variant disease-association studies can be
very rewarding [7–9].
Identification of de novo mutations
Because of the above-described challenges, study designs to filter
the number of potential variants contributing to disease have been
developed. One of them is to look for de novo mutations using a
trio-design, that is, by sequencing the affected offspring and bothparents. On an average each of us carries about 0.8–1.3 de novo
mutations in our exome, not detectable in parents (the human
genome mutation rate has been estimated to be 1.1–3  108 in a
haploid genome per base per generation [10]). The trio-design has
stimulated studies especially in the field of neurodevelopmental
traits [11–13]. These results have provided a list of candidate genes
that are awaiting future validation. In more than 900 autism trio-
studies one consistent finding is that while the number of de novo
events is not higher in affected autism offspring in comparison
with control subjects, the ratio of nonsense versus missense var-
iants is clearly higher in autism trio-cases. So far, trio-studies have
highlighted the need for even larger sample sizes, even in a design
where the number of candidate variants can be efficiently filtered
down by only focusing on de novo events.
Random population-based and family-based study
designs
There is high interest in identifying also other types of rare disease-
predisposing variants than de novo mutations. Studies utilizing
both family and case–control designs are in progress. These
include large studies such as the UK10K project that aims to
sequence 4000 low-coverage whole genomes from the UK-Twin
and ALSPAC cohorts and 6000 exomes from patients with selected
diseases, including extreme obesity, ten different rare diseases,
autism and schizophrenia. When writing this, the project is still in
progress and it is still too early to evaluate its success. The data are
not sufficient to guide the estimation of risk ratios associated with
low-frequency (population frequency 0.5–5%) and rare (<0.5%)
variants. However, it remains unlikely that there are many high-
effect size variants contributing to the disease susceptibility in
complex traits. If we speculate that typical effect sizes range
between 1.2 and 3.0, we can foresee a need for sample sizes that
are even bigger than in GWA-studies. Figures 1 and 2 demonstratewww.elsevier.com/locate/nbt 293
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FIGURE 2
Statistical power to detect association between various low frequency
variants, effect sizes, and disease for sample size of 10 000 cases and 10 000
controls. P < 5  108 is assumed for genome-wide significant association.
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variants and disease for different allele frequencies and effect sizes.
In Fig. 1, a sample size of 2000 cases and 2000 controls is assumed.
Similarly, in Fig. 2, 10,000 cases and 10,000 controls are assumed.
Family-designs have been suggested to provide benefits and
shortcuts also in sequencing studies of complex traits. The hypoth-
esis is that an excess of disease susceptibility variants are clustered
and more frequent in families with a specific disease than in the
control population. Only a few family members need to be fully
sequenced, whereas the remaining relatives can be more sparsely
genotyped and the full genome variation can be imputed. The
segregation of a disease-associated haplotype can then be traced in
the full pedigree. Yet, the optimal statistical family-based analysis
in complex traits is not fully worked out. The classical linkage
analysis that emerged from a highly penetrant Mendelian type of
mutation scenario might be too simplistic for complex traits. As
stated above, the functional interplay of variants (variants might
have different effects in different genetic backgrounds) might be
complicated, resulting in substantially decreased power in trans-
mission-based analyses. Thus it is probable that also family-based
analyses will need large sample sizes to achieve statistically robust
results. Recent studies from Iceland have demonstrated that
extending the pedigree-design to ‘mega pedigree approaches’
and imputation using genealogical records or long-range haplo-
type matching can be highly effective [14].
Population isolates
An extension of the ‘mega pedigree’ concept is to use population
isolates to identify low-frequency and rare disease-causing
alleles. Because of bottleneck effects, genetic drift and popula-
tion expansion some rare alleles are enriched in population
isolates like Finland. The hypothesis is that some of these alleles,
which are extremely rare (population frequency < 0.1%), for294 www.elsevier.com/locate/nbtexample, in most European populations, have been enriched
to frequencies between 1 and 5% in the population isolate. Some
of the enriched variants might contribute to common diseases.
Even though they could be neutral in an environment where the
founder population was established more than thousand years
ago, they may contribute to diseases in the modern lifestyle and
environment. An enrichment of low-frequency alleles in the
study population should boost the power significantly compared
to more mixed populations. Therefore, the expectation is that
smaller discovery sets are needed to achieve significant associa-
tion in population isolates.
Additional to the benefits provided by the population struc-
ture, the Scandinavian health records, population cohorts and
clinical sample collections are unique. These facts have stimu-
lated several individual large whole-exome and whole-genome
sequencing projects, which have organized themselves in a col-
laborative initiative called SISu (Sequencing Initiative Suomi
(Suomi is the Finnish name for Finland)). By the end of 2012
we expect to have completed the sequencing of 8000 Finnish
genomes or exomes. In addition, genome-wide association
(GWA) data are available for about 40 000 Finns, complemented
in many cases by low frequency variant genotype data (e.g.
cardiometabo and exome chip). In a population isolate, like Fin-
land, we expect that this will provide an exceptional imputation
framework. Using this combined genome information we expect
to impute a near complete genome variant set, enabling large-
scale, low-cost custom genotyping in the entire collection of
200 000 individual’s samples stored in the National Biobank
(www.nationalbiobanks.fi). A well-characterized collection of
samples, with near complete genome variant information and
rich phenotypic and health record information, would provide a
unique data-resource and reference database for building tools for
personalized/precision medicine.
From sequences towards personalized medicine
High throughput omics techniques provide opportunities to envi-
sion new medical and health care paradigms. Evidence-based
medicine, which lies at the heart of current western approaches
to healthcare, relies mainly on the statistical interpretation of data
from large clinical trials. Although this is a well-tested strategy that
will continue to inform medical practice, it is limited by a general
failure to take into account more than a few personalized indica-
tors such as, for example, sex, age, weight and smoking status.
Therapeutic decisions that currently are based on average values
from large studies, irrespective of a patient’s individual character-
istics and treatment strategies are therefore not always effectively
targeted. Great hopes are being invested in personalized and
stratified medicine as a form of health care that is better tailored
to meet the individuals’ needs. An essential component of this aim
is that complete individual genome sequences become a compo-
nent of future clinical decision-making. Such projects as the SISu
initiative would contribute by providing large and well-character-
ized reference datasets for implementing genomics in future clin-
ical settings. The advantage of the individual sequence is that it,
for many purposes, needs to be determined only once, and can be
used multiple times over the life-course of an individual for
diagnostic and therapeutic applications. The dramatically decreas-
ing cost of sequencing will make sequencing only a minor fraction
New Biotechnology Volume 30, Number 3 March 2013 RESEARCH PAPERof average lifetime health costs. As a result, cumulative savings can
be achieved over time.
Analyses of the complete spectrum of genome variants
will create new analytical challenges and study design require-
ments. As stated above, tackling of these challenges requires large,
well-documented data collections so that a large spectrum of riskcombinations can be tested. Special populations provide specific
opportunities to pioneer this task, and the Nordic countries
provide unique advantages for these study designs. Yet, the
procedures integrating very complex multilayer data and the
development of tools that are helpful in clinical decision-making
and health care need a lot of research.ReferencesR
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